EGFR and non-small cell lung carcinoma: Meanwhile, recently, a post hoc analysis from NEJ002 was conducted to examine the efficacy of dose-reduction gefitinib compared with that of standard-dose gefitinib in EGFR-mutated NSCLC patients.